Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Equities research analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Recursion Pharmaceuticals in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.45) per share for the year, up from their prior forecast of ($1.57). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.54) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q4 2024 earnings at ($0.33) EPS and FY2025 earnings at ($1.40) EPS.

Several other brokerages also recently commented on RXRX. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research note on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $9.40.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded up $0.56 on Monday, hitting $7.66. 13,410,530 shares of the company traded hands, compared to its average volume of 5,708,225. The company has a current ratio of 4.35, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The business's 50 day moving average price is $6.57 and its 200-day moving average price is $7.62. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -5.25 and a beta of 0.81. Recursion Pharmaceuticals has a 52-week low of $5.22 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. During the same period in the previous year, the business posted ($0.43) earnings per share. The company's revenue for the quarter was up 147.6% on a year-over-year basis.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of RXRX. ARK Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock worth $215,949,000 after purchasing an additional 4,626,268 shares in the last quarter. Baillie Gifford & Co. lifted its position in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company's stock valued at $199,425,000 after acquiring an additional 2,522,132 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 2.2% in the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company's stock worth $159,667,000 after acquiring an additional 349,554 shares during the last quarter. Kinnevik AB publ increased its position in shares of Recursion Pharmaceuticals by 14.4% during the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company's stock worth $89,293,000 after purchasing an additional 1,500,000 shares in the last quarter. Finally, Lingotto Investment Management LLP raised its stake in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company's stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company's stock, valued at $3,939,803.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00. Following the completion of the transaction, the chief financial officer now owns 1,340,968 shares of the company's stock, valued at $8,515,146.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 171,682 shares of company stock worth $1,107,868 over the last quarter. Insiders own 15.75% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.